Literature DB >> 11319603

p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells.

A P MacLaren1, R S Chapman, A H Wyllie, C J Watson.   

Abstract

We have examined the effects of inhibition of the 26S proteasome in a murine mammary cell line, KIM-2 cells using the peptide aldehyde inhibitor MG132. These studies have demonstrated a clear requirement for proteasome function in cell viability. Induction of apoptosis was observed following MG132 treatment in KIM-2 cells and this death was shown to be dependent on the cell actively traversing the cell cycle. KIM-2 cells were generated using a temperature sensitive T-antigen (Tag) and studies at the permissive temperature (33 degrees C) have shown that a Tag binding protein was essential for this apoptotic response. Studies in two additional cell lines, HC11, which is a mammary epithelial cell line carrying mutant p53 alleles and p53 null ES cells suggest that p53 is actively required for the apoptosis induced as a consequence of proteasome inhibition. These results suggest a pivotal role for the 26S proteasome degradation pathway in progression through the cell cycle in proliferating cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319603     DOI: 10.1038/sj.cdd.4400801

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  17 in total

Review 1.  Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy.

Authors:  Yanfen Liu; Yihong Ye
Journal:  Cell Res       Date:  2011-05-03       Impact factor: 25.617

2.  The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.

Authors:  Azmi Yerlikaya; Emrah Okur; Engin Ulukaya
Journal:  Tumour Biol       Date:  2012-04-04

3.  Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines.

Authors:  Ana-Matea Mikecin; Leslie R Walker; Marija Kuna; Drazen Raucher
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

4.  MG132 inhibition of proteasome blocks apoptosis induced by severe DNA damage.

Authors:  Ling Zhang; Jennifer J Hu; Feng Gong
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

5.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

6.  Proteasome inhibitors induce p53-independent apoptosis in human cancer cells.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

7.  Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.

Authors:  Koichi Okamoto; Aziz Zaanan; Hisato Kawakami; Shengbing Huang; Frank A Sinicrope
Journal:  Mol Cancer Res       Date:  2014-12-29       Impact factor: 5.852

Review 8.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  BAX/BAK-independent mitoptosis during cell death induced by proteasome inhibition?

Authors:  Elena Lomonosova; Jan Ryerse; G Chinnadurai
Journal:  Mol Cancer Res       Date:  2009-08-11       Impact factor: 5.852

10.  BU-32: a novel proteasome inhibitor for breast cancer.

Authors:  Joseph K Agyin; Bindu Santhamma; Hareesh B Nair; Sudipa S Roy; Rajeshwar R Tekmal
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.